Lipocine reports FY2025 net loss of $9.6M; cash $14.9M; PPD Phase 3 topline due April 2026

Lipocine Inc.

Net loss of $9.6M ($1.69/diluted) vs $8K net income in FY2024; revenue fell to $2.0M from $11.2M.
Cash and equivalents $14.9M at Dec 31, 2025, increased to $24.7M post-ATM offering in Q1 2026.
Phase 3 study of LPCN 1154 (PPD) completed last patient visit; topline data expected early April 2026.
R&D expenses rose to $8.6M from $7.4M on higher clinical study costs; G&A down to $3.8M.
Company plans 505(b)(2) NDA submission for LPCN 1154 in mid-2026 if Phase 3 successful.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lipocine Inc. reported the full year ended December 31, 2025 results: revenue $2.0 million, net income net loss of $9.6 million, EPS ($1.69) per diluted share.

Period: the full year ended December 31, 2025
Revenue: $2.0 million
Net income: net loss of $9.6 million
EPS: ($1.69) per diluted share
Result: reported results

Exact text from the filing

per diluted share, for the year ended December 31, 2025, compared with net income of $8,352, or ($0.00) per diluted share, for the year ended December 31, 2024. Revenues were $2.0 million during the year ended December 31, 2025, compared to revenue of $11.2 million during the year ended December 31, 2024. Revenue in 2025 primarily consisted of license revenue from

View on SEC.gov

Browse all earnings releases →

Lipocine Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-009428

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.